Anixa Biosciences (ANIX) investor relations material

Financial position and business strategy

• Maintains a strong balance sheet with $14 million in cash, no debt, and a clean capital structure as of April 30th.

• Annual cash burn is low at $5–7 million, supported by partnerships with leading institutions.

• Consistent insider buying, including over $2.5 million in open market purchases by leadership.

• Leverages partnerships with Cleveland Clinic and Moffitt Cancer Center to minimize overhead.

• Plans to out-license programs to pharmaceutical companies for commercialization.

Clinical pipeline and innovation

• Two clinical-stage programs: CAR-T therapy for ovarian cancer and a breast cancer vaccine.

• CAR-T therapy targets recurrent, resistant ovarian cancer and is in phase I at Moffitt Cancer Center.

• Breast cancer vaccine, partnered with Cleveland Clinic and funded by the U.S. Department of Defense, completed phase I and is preparing for phase II.

• Both programs show promising clinical data and address large oncology markets.

CAR-T therapy for ovarian cancer

• Utilizes engineered T-cells targeting the follicle-stimulating hormone receptor, expressed mainly on ovaries and tumor vasculature.

• Direct peritoneal delivery enhances targeting and reduces systemic side effects.

• Demonstrated improved survival in heavily pretreated patients, with some exceeding expected survival by over two years.

• Ongoing dose escalation with 14 patients treated and further cohorts planned.